Abstract
We longitudinally assessed P. falciparum parasite kinetics, gametocyte production and infectivity in incident infections that were naturally acquired following infection clearance and in chronic asymptomatic infections in Burkina Faso. 92% (44/48) of the incident cohort developed symptoms and were treated within 35 days, compared to 23% (14/60) of the chronic cohort. All but two individuals with chronic infection were gametocytaemic at enrollment, whereas only 35% (17/48) in the incident cohort developed gametocytes within 35 days. The relative abundance of ap2-g transcripts was positively associated with conversion to gametocyte production (i.e. the ratio of gametocytes at day 14 to ring stage parasites at baseline) and was higher in chronic infections. Parasite multiplication rate, assessed by daily molecular parasite quantification, was positively associated with prospective gametocyte production. Most incident infections were cleared before gametocyte density was sufficiently high to infect mosquitoes. In contrast, chronic, asymptomatic infections represented a significant source of mosquito infections. If present, gametocytes were significantly less infectious if concurrent with malaria symptoms. Our observations support the notion that malaria transmission reduction may be expediated by enhanced case management, involving both symptom-screening and infection detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a fellowship from the European Research Council (ERC-2014-StG 639776), the Bill and Melinda Gates Foundation (INDIE OPP1173572) and the Radboud-Glasgow Collaboration Fund. JB received support from the UK MRC and the UK DFID (#MR/K012126/1) under the MRC/DFID Concordat agreement and as part of the EDCTP2 programme supported by the European Union
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* joint first authors
Data Availability
Data will be deposited in Dryad upon publication
